Mirnas involved in the blood brain barrier function
AssigneeVereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg
InventorsArie Reijerkerk, Helga Eveline De Vries
Life of this patent
Estimating the term…
Abstract
The current invention relates to use of particular nucleic acids for modulating (increasing or decreasing) blood-brain barrier function, and for use of such nucleic acids in treatment of conditions involving blood brain barrier function, including multiple sclerosis, HIV infection, Alzheimer's disease, Parkinson's disease, epilepsy, and so on. Also provided is an assay for identifying drugs useful in modulating blood brain barrier function.
Claims26
A method for increasing blood-brain barrier function, comprising introducing to or expressing in brain endothelial cells a nucleic acid comprising a nucleic acid sequence which has at least 70%, preferably 75%, more preferably 80%, even more preferably 85%, even more preferably 90%, even more preferably 95%, most preferably 100% sequence identity with a nucleic acid sequence selected from the group consisting of SEQ ID No 1-152.
A nucleic acid comprising a nucleic acid sequence which has at least 70%, preferably 75%, more preferably 80%, even more preferably 85%, even more preferably 90%, even more preferably 95%, most preferably 99% sequence identity with a nucleic acid sequence selected from the group consisting of SEQ ID No 1-152, wherein said nucleic acid is not a nucleic acid sequence selected from the group consisting of SEQ ID No 1-152.
A method for decreasing blood-brain barrier function, comprising blocking a nucleic acid which comprises the nucleic acid sequence selected from the group of SEQ ID NO:1-152 with a blocking nucleic acid comprising a nucleic acid sequence of which at least 8 adjacent nucleotides are at least 70%, preferably 75%, more preferably 80%, even more preferably 85%, even more preferably 90%, even more preferably 95%, most preferably 100% complementary to 8 adjacent nucleotides of a nucleic acid sequence selected from the group of SEQ ID No 1-152.
(canceled)
The method according to claim 25, wherein the nucleic acid delivery vehicle is introduced in a cell, preferably a brain endothelial cell.
An assay for screening for compounds that modulate the blood brain barrier function comprising the steps of:
- incubating a cell in the presence of a compound to be tested,
- determining the expression level of a nucleic acid sequence selected from the group of SEQ ID No 1-152,
- wherein the expression level of said nucleic acid sequence is compared with the expression level of said nucleic acid sequence as determined in a cell incubated without the presence of said compound to be tested.
Dependencies are inferred from the claim text.